活化蛋白C：性价比高还是成本高昂？
Activated protein C: cost-effective or costly?
作者信息
Brar Savtaj Singh, Manns Braden J
出版信息
Crit Care. 2007;11(5):164. doi: 10.1186/cc6090.
Abstract
The authors offer a commentary on the study by Dhainaut et al. on the cost-effectiveness of activated protein C in severe sepsis. Using data from "real world" conditions, the results of this economic evaluation are consistent with previous analyses, and highlight the need for "real world" investigations of new health technologies in critical care.
摘要
作者们对Dhainaut等人关于活化蛋白C在严重脓毒症中成本效益的研究进行了评论。利用“现实世界”条件下的数据，这项经济评估的结果与之前的分析一致，并突出了对重症监护中新卫生技术进行“现实世界”调查的必要性。
相似文献
1
Activated protein C: cost-effective or costly?活化蛋白C：性价比高还是成本高昂？
Crit Care. 2007;11(5):164. doi: 10.1186/cc6090.
2
Cost-effectiveness of activated protein C in real-life clinical practice.活化蛋白C在实际临床实践中的成本效益
Crit Care. 2007;11(5):R99. doi: 10.1186/cc6116.
3
Pro/Con debate of activated protein C in severe sepsis.活化蛋白C用于严重脓毒症的利弊辩论
Crit Care Med. 2003 Aug;31(8):2249. doi: 10.1097/01.CCM.0000087327.59341.18.
4
[Activated C protein in severe sepsis].
Anesteziol Reanimatol. 2004 Jul-Aug(4):50-1.
5
Severe sepsis in a premature neonate: protein C replacement therapy.
Turk J Pediatr. 2008 Jul-Aug;50(4):405-8.
6
Activated protein C for the treatment of severe sepsis.活化蛋白C治疗严重脓毒症
Clin Microbiol Infect. 2009 Apr;15(4):319-24. doi: 10.1111/j.1469-0691.2009.02751.x.
7
[Medical-economic evaluation of severe sepsis].[严重脓毒症的医学经济学评估]
Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:28-30.
8
Activated protein C: controversy and hope in the treatment of sepsis.活化蛋白C：脓毒症治疗中的争议与希望
Curr Opin Investig Drugs. 2007 Nov;8(11):933-8.
9
[Activated protein C].
Rinsho Byori. 2011 Feb;Suppl 147:171-6.
10
First sepsis drug nears market.
Nat Med. 2001 May;7(5):516-7. doi: 10.1038/87809.
引用本文的文献
1
Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis.克拉霉素可提高呼吸机相关性肺炎和脓毒症患者的长期生存率并带来成本效益。
Antimicrob Agents Chemother. 2016 May 23;60(6):3640-6. doi: 10.1128/AAC.02974-15. Print 2016 Jun.
2
Regulation of the protein C anticoagulant and antiinflammatory pathways.蛋白 C 抗凝和抗炎途径的调节。
Curr Med Chem. 2010;17(19):2059-69. doi: 10.2174/092986710791233706.
本文引用的文献
1
Cost-effectiveness of activated protein C in real-life clinical practice.活化蛋白C在实际临床实践中的成本效益
Crit Care. 2007;11(5):R99. doi: 10.1186/cc6116.
2
Economic evaluation in critical care medicine.重症医学中的经济评估
J Crit Care. 2006 Jun;21(2):117-24. doi: 10.1016/j.jcrc.2006.02.003.
3
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.重组人活化蛋白C治疗伴有多器官功能衰竭的严重脓毒症的成本效益分析
Int J Technol Assess Health Care. 2006 Winter;22(1):101-8. doi: 10.1017/s0266462306050896.
4
Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.在英国评估重组人活化蛋白C（drotrecogin alfa）治疗严重脓毒症的成本效益。
Int J Technol Assess Health Care. 2006 Winter;22(1):90-100. doi: 10.1017/s0266462306050884.
5
When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated).当一项关键试验并不足够时——重组人活化蛋白C的案例
Intensive Care Med. 2006 Apr;32(4):604; author reply 610-2. doi: 10.1007/s00134-006-0086-9. Epub 2006 Mar 1.
6
Whither trial-based economic evaluation for health care decision making?基于试验的卫生保健决策经济评估何去何从？
Health Econ. 2006 Jul;15(7):677-87. doi: 10.1002/hec.1093.
7
The desirability and feasibility of economic studies of drugs post-launch.
Eur J Health Econ. 2006 Mar;7(1):5-6. doi: 10.1007/s10198-006-0337-2.
8
Activated protein C: do more survive?活化蛋白C：更多患者能存活吗？
Intensive Care Med. 2005 Dec;31(12):1624-6. doi: 10.1007/s00134-005-2829-4. Epub 2005 Oct 15.
9
An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.评估活化蛋白C相对于器官系统衰竭数量的成本效益。
Pharmacoeconomics. 2003;21(18):1331-40. doi: 10.1007/BF03262331.
10
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.重组人活化蛋白C治疗严重脓毒症的成本效益分析
Crit Care Med. 2003 Jan;31(1):1-11. doi: 10.1097/00003246-200301000-00001.
Zotero 插件